Zydus Cadila
Aug 06, 2020
Zydus starts Phase II COVID-19 vaccine trial; Taysha raises $95M; FDA declines DBV’s peanut allergy patch; Combating COVID-19 with decoy target
Zydus starts phase 2 COVID-19 vaccine trial after clearing safety test Zydus Cadila has finished a phase 1 clinical trial of its COVID-19 vaccine ZyCoV-D, setting it up to move straight into a 1,000-subject phase 2 study. The Indian company informed that the DNA vaccine was well tolerated in the first stage of t...
Read More...
Jul 29, 2020
In The Global Race For The COVID-19 Vaccine, India Stands As A Strong Player
India registered its first COVID-19 case on 30-January-2020 in Kerala. The cases since then are on a continuous rise. The Government of India in order to contain the spread of novel coronavirus rolled out several guidelines and precautionary measures. The situation worldwide was so serious that the whole nation was...
Read More...
Feb 21, 2017
USFDA warns; Vit B3 prevents glaucoma; Zydus Cadila receives nod; U.S. experts soften on DNA editing
USFDA warns Bengaluru-based Resonance Labs of manufacturing norms violations US health regulator USFDA has red-flagged significant deviations from manufacturing norms at the Bengaluru-based API facility of Resonance Laboratories, including failure to have adequate cleaning procedures to prevent contamination of prod...
Read More...
Sep 22, 2016
Sygnis AG and ECACC Collaboration; BioNTech and Genentech Partnership; Partnership between Zydus Cadila and Takeda; Global Agreement between Regeneron Pharmaceuticals, Inc. and Teva Pharmaceutical
Collaboration between Sygnis AG and ECACC for licensing and distribution of Caco-2 cell line Sygnis AG enters into a collaboration agreement with ECACC to significantly expand Sygnis' Caco-2 business. Under the collaboration, ECACC will organize that companies obtain the license for the use of the Caco-2 cell line f...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
